NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

NBSE

NBSENeuBase Therapeutics, Inc. US flag

NASDAQ Capital Market

0.38

USD

-0.01

- -

1.42MMarket Cap

NeuBase Therapeutics, Inc.

NBSE

(NASDAQ Capital Market)

Recent

price

0.38

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Jasper Therapeutics, Inc. (JSPRW)
Onward Medical N.V. (ONWD.BR)
9 Meters Biopharma, Inc. (NMTRQ)
Telix Pharmaceuticals Limited (TLX.AX)
Abpro Holdings, Inc. (ABPO)
Hubei Goto Biopharm Co.,Ltd. (300966.SZ)
Business: NeuBase Therapeutics, Inc. is a pre-clinical stage biopharmaceutical company headquartered in Pittsburgh, Pennsylvania, focused on developing precision genetic medicines for rare and dominant genetic neurological disorders. The company’s core product platform, PATrOL™, utilizes synthetic peptide-nucleic acid antisense oligonucleotides combined with innovative delivery shuttles to selectively target and silence disease-causing RNA mutations without affecting healthy genes. Its product pipeline targets debilitating conditions such as Huntington’s disease, myotonic dystrophy type 1 (DM1), familial Parkinson’s disease, and oncogenic mutations including the mutated KRAS gene. NeuBase aims to address unmet medical needs in neurological, neuromuscular, and oncologic diseases through its proprietary gene-silencing therapies. Recent major changes include a strategic shift following financial challenges that led the company to discontinue development of its Stealth Editor gene-editing program and reduce staff substantially in 2023. The board has considered dissolution and explored strategic alternatives such as mergers, acquisitions, or business combinations. As of 2023-2024, NeuBase also completed a $5 million financing round and has engaged in efforts to stabilize and refocus its pipeline on its core PATrOL technology. The company has received regulatory and shareholder approvals to maintain NASDAQ listing and explored partnerships to advance preclinical development. These operational realignments reflect an emphasis on advancing RNA-targeted therapies with improved safety and delivery profiles. Founded in 2009, NeuBase operates primarily in the United States and serves patients with rare genetic disorders through its innovative therapeutic modalities. The company maintains a strong scientific foundation in synthetic oligonucleotide chemistry and gene silencing, aiming to leverage its PATrOL platform as a versatile tool for systemic delivery of genetic medicines. Its commitment to precision medicine positions NeuBase as a notable entity in the evolving biotech sector targeting neurogenetic and oncologic diseases. Overall, NeuBase Therapeutics, Inc. specializes in synthetic RNA-targeted genetic therapies mainly for rare neurological diseases, with recent corporate restructuring focused on sustainable growth through its proprietary PATrOL platform and selective development pipeline targeting Huntington's disease, myotonic dystrophy, familial Parkinson’s, and certain oncogenic mutations, amidst efforts to address financial constraints and strategic realignments since 2023.

Company News